Xvivo Perfusion AB (FRA:3XV) Cyclically Adjusted FCF per Share: €0.14 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:3XV Xvivo Perfusion AB FRA:3XV
85 GF Score
Price €21.00
GF Value €35.15
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Xvivo Perfusion AB Cyclically Adjusted FCF per Share?

Xvivo Perfusion AB FRA:3XV -2.23% 85 Cyclically Adjusted FCF per Share is €0.14 as of Jun. 2026. GuruFocus rates FRA:3XV with a GF Score™ of 85/100 and a GF Value™ of €35.15 (Significantly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Xvivo Perfusion AB's adjusted free cash flow per share for the three months ended in Jun. 2026 was €0.184. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €0.14 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Xvivo Perfusion AB's average Cyclically Adjusted FCF Growth Rate was 64.60% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 33.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Xvivo Perfusion AB was 33.20% per year. The lowest was 33.20% per year. And the median was 33.20% per year.

As of today (2026-07-23), Xvivo Perfusion AB's current stock price is €21.00. Xvivo Perfusion AB's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was €0.14. Xvivo Perfusion AB's Cyclically Adjusted Price-to-FCF of today is 150.00.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Xvivo Perfusion AB was 728.38. The lowest was 137.77. And the median was 424.24.


Xvivo Perfusion AB  (FRA:3XV) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Xvivo Perfusion AB's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=21.00/0.14
=150.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Xvivo Perfusion AB was 728.38. The lowest was 137.77. And the median was 424.24.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Xvivo Perfusion AB Cyclically Adjusted FCF per Share Related Terms


Xvivo Perfusion AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Xvivo Perfusion AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xvivo Perfusion AB Cyclically Adjusted FCF per Share Chart

Xvivo Perfusion AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.05 0.06 0.09 0.12

Xvivo Perfusion AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.09 0.12 0.13 0.14

FRA:3XV vs ABT, SYK, MDT: Cyclically Adjusted FCF per Share Comparison

For the Medical Devices subindustry, Xvivo Perfusion AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xvivo Perfusion AB Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's Cyclically Adjusted Price-to-FCF falls into.


FRA:3XV
85GF Score
Xvivo Perfusion AB FRA:3XV
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xvivo Perfusion AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Xvivo Perfusion AB's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.184/134.1100*134.1100
=0.184

Current CPI (Jun. 2026) = 134.1100.

Xvivo Perfusion AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 0.024 101.138 0.032
201612 -0.027 102.022 -0.035
201703 -0.009 102.022 -0.012
201706 0.026 102.752 0.034
201709 0.030 103.279 0.039
201712 0.030 103.793 0.039
201803 0.034 103.962 0.044
201806 0.082 104.875 0.105
201809 0.013 105.679 0.016
201812 -0.009 105.912 -0.011
201903 0.000 105.886 0.000
201906 0.074 106.742 0.093
201909 0.054 107.214 0.068
201912 -0.026 107.766 -0.032
202003 0.032 106.563 0.040
202006 0.009 107.498 0.011
202009 -0.006 107.635 -0.007
202012 -0.075 108.296 -0.093
202103 0.034 108.360 0.042
202106 -0.045 108.928 -0.055
202109 -0.029 110.338 -0.035
202112 -0.002 112.486 -0.002
202203 -0.030 114.825 -0.035
202206 -0.005 118.384 -0.006
202209 0.053 122.296 0.058
202212 0.067 126.365 0.071
202303 -0.037 127.042 -0.039
202306 0.045 129.407 0.047
202309 0.070 130.224 0.072
202312 0.051 131.912 0.052
202403 0.004 132.205 0.004
202406 0.069 132.716 0.070
202409 0.064 132.304 0.065
202412 0.171 132.987 0.172
202503 -0.044 132.825 -0.044
202506 0.025 133.699 0.025
202509 0.059 133.480 0.059
202512 0.253 133.390 0.254
202603 0.192 133.560 0.193
202606 0.184 134.110 0.184

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €0.14 mean?
Xvivo Perfusion AB (FRA:3XV) has a Cyclically Adjusted FCF per Share of €0.14 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Xvivo Perfusion AB and its competitors.
Is Xvivo Perfusion AB's Cyclically Adjusted FCF per Share too high?
Xvivo Perfusion AB's current Cyclically Adjusted FCF per Share is €0.14. Overall, Xvivo Perfusion AB has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Cyclically Adjusted FCF per Share compare to ABT and SYK?
Xvivo Perfusion AB's Cyclically Adjusted FCF per Share of €0.14 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Xvivo Perfusion AB and its competitors. Xvivo Perfusion AB's current Cyclically Adjusted FCF per Share is €0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (FRA:3XV) is currently considered Significantly Undervalued. The stock's GF Value™ is €35.15, compared to a current price of €21.00 — trading 40.3% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €0.14. Xvivo Perfusion AB's overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Xvivo Perfusion AB (FRA:3XV), the current Cyclically Adjusted FCF per Share is €0.14 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xvivo Perfusion AB (FRA:3XV) Overvalued in 2026?

Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued. The current stock price of €21.00 is trading 40.3% below its estimated GF Value™ of €35.15. GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.

Key valuation signals for FRA:3XV:

  • Cyclically Adjusted FCF per Share: €0.14
  • GF Value™: €35.15 vs. price of €21.00 (40.3% below fair value)
  • GF Score™: 85/100 with 2 warning signs

No single metric tells the full story. See the FRA:3XV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xvivo Perfusion AB Business Description

Address Gemenskapens gata 9, Molndal, SWE, SE-431 53
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
85GF Score

Get the complete analysis for FRA:3XV

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.00
Price
€35.15
GF Value